Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravindran Ankathil

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Pharmacogenomics and Personalized Medicine|May 27, 2017
<i>ABCB1</i> genetic variants in leukemias: current insights into treatment outcomesRavindran Ankathil
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|August 6, 2015
Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genesShing Cheng Tan, Ravindran Ankathil
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 18, 2011
Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detectionKa Liong Tan, Ravindran Ankathil, Siew Hua Gan
Journal of Maxillofacial and Oral Surgery|August 19, 2021
Next-Generation Sequencing in CancerS Vinod Nair, Madhulaxmi, Gigi Thomas, et al.
Journal of Genetics|September 29, 2018
Genetic variations in influx transporter gene <i>SLC22A1</i> are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patientsSiti Maziras Makhtar, Azlan Husin, Abdul Aziz Baba, et al.
Cardiovascular & Hematological Disorders Drug Targets|April 20, 2018
Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia PatientsMarjanu Hikmah Elias, Husin Azlan, Abdul Aziz Baba, et al.
Pharmacogenomics|March 24, 2018
Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An updateRavindran Ankathil, Husin Azlan, Abu Abdullah Dzarr, et al.
International Journal of Breast Cancer|April 21, 2020
Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy RegimenAhmad Aizat Abdul Aziz, Md Salzihan Md Salleh, Ravindran Ankathil
Journal of Genetics|September 27, 2017
Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patientsSiti Maziras Makhtar, Azlan Husin, Abdul Aziz Baba, et al.
Cancer Reports (Hoboken, N.J.)|July 29, 2020
Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patientsMarjanu Hikmah Elias, Husin Azlan, Sarina Sulong, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Pharmacogenomics and Personalized Medicine|May 27, 2017
<i>ABCB1</i> genetic variants in leukemias: current insights into treatment outcomesRavindran Ankathil
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|August 6, 2015
Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genesShing Cheng Tan, Ravindran Ankathil
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 18, 2011
Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detectionKa Liong Tan, Ravindran Ankathil, Siew Hua Gan
Journal of Maxillofacial and Oral Surgery|August 19, 2021
Next-Generation Sequencing in CancerS Vinod Nair, Madhulaxmi, Gigi Thomas, et al.
Journal of Genetics|September 29, 2018
Genetic variations in influx transporter gene <i>SLC22A1</i> are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patientsSiti Maziras Makhtar, Azlan Husin, Abdul Aziz Baba, et al.
Cardiovascular & Hematological Disorders Drug Targets|April 20, 2018
Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia PatientsMarjanu Hikmah Elias, Husin Azlan, Abdul Aziz Baba, et al.
Pharmacogenomics|March 24, 2018
Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An updateRavindran Ankathil, Husin Azlan, Abu Abdullah Dzarr, et al.
International Journal of Breast Cancer|April 21, 2020
Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy RegimenAhmad Aizat Abdul Aziz, Md Salzihan Md Salleh, Ravindran Ankathil
Journal of Genetics|September 27, 2017
Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patientsSiti Maziras Makhtar, Azlan Husin, Abdul Aziz Baba, et al.
Cancer Reports (Hoboken, N.J.)|July 29, 2020
Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patientsMarjanu Hikmah Elias, Husin Azlan, Sarina Sulong, et al.
Pageof 6